Skip to main content
SpringerLink
Log in

Variable effects of tamoxifen on human hematopoietic progenitor cell growth and sensitivity to doxorubicin

  • Original Articles
  • Tamoxifen, Doxorubicin, Marrow
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

To determine the influence of tamoxifen on the drug sensitivity of normal human hematopoietic progenitor cells, T-cell- and adherent-cell depleted human bone marrow mononuclear cells (T−, Ad−) were exposed in vitro to 5 μM tamoxifen for 24 h. The effects of tamoxifen were highly variable, as exposure to tamoxifen produced an increase (97%±12.3%) in the growth of day-12 committed myeloid progenitors (CFU-GM) in only four of ten experiments utilizing bone marrow from different donors. When T−, Ad− myeloid progenitor cells treated with tamoxifen were subsequently exposed to doxorubicin, 7 of 14 experimental samples studied demonstrated a net increase in the number of surviving clonogenic cells as compared with cells exposed to doxorubicin alone. Tamoxifen also stimulated the growth of a more purified (CD34+-selected) progenitor cell population in four of four experiments (by 62.5%±4.9%) but did not increase the survival of these cells upon exposure to doxorubicin; in fact, in five of ten experimental samples, tamoxifen enhanced cell sensitivity to doxorubicin. Taken together, these observations indicate that tamoxifen produces variable stimulation of committed myeloid progenitor cell growth in vitro. Furthermore, while under some circumstances, tamoxifen appears to have the capacity to enhance CFU-GM survival in the presence of doxorubicin, this drug combination may also result in enhanced toxicity to normal bone marrow progenitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CFU-GM:

granulocyte-macrophage colony-forming units

T−, Ad− :

T-cell- and adherent-cell-depleted bone marrow mono-nuclear cells

References

  1. Auber ML, Horwitz LJ, Blaauw A, Khorana S, Tucker S, Woods T, Warmuth M, Dicke KA, McCredie KB, Spitzer G (1988) Evaluation of drugs for elimination of leukemic cells from the bone marrow of patients with acute leukemia. Blood 71: 166

    Google Scholar 

  2. Berman E, Adams M, Duigou-Osterndort R, Godfrey L, Clarkson B, Andreeff M (1991) Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 77: 818

    Google Scholar 

  3. Burgess AW, Wilson EMA, Metcalf D (1977) Stimulation of human placental conditioned medium of hematopoietic colony formation by human marrow cells. Blood 49: 573

    Google Scholar 

  4. Chaudhary PM, Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85

    Google Scholar 

  5. Chatterjee M, Harris AL (1990) Reversal of acquired resistance to Adriamycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen: role of drug interaction with alpha 1 acid glycoprotein. Br J Cancer 62: 712

    Google Scholar 

  6. Engleman EG, Warnke R, Fox RI, Dilley J, Benike CJ, Levy R (1981) Studies of T lymphocyte antigen recognized by a monoclonal antibody. Proc Natl Acad Sci USA 78: 1791

    Google Scholar 

  7. Fei L, Grant S, Pettit GR, McCrady CW (1992) Bryostatin 1 modulates the proliferation and lineage commitment of human myeloid progenitor cells exposed to recombinant interleukin-3 and recombinant granulocyte-macrophage colony-stimulating factor. Blood 80: 495

    Google Scholar 

  8. Fine RL, Koizumi S, Curt GA, Chabner BA (1987) Effect of calcium channel blockers on human CFU-GM with cytotoxic drugs. J Clin Oncol 5: 489

    Google Scholar 

  9. Foster BJ, Grotzinger KR, McCoy WM, Rubinstein LV, Hamilton TC (1988) Modulation of induced resistance to Adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. Cancer Chemother Pharmacol 22: 147

    Google Scholar 

  10. Geisinger KR, Berens ME, Duckett Y, Morgan TM, Kute TE, Welander CE (1990) The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro. Cancer 65: 1055

    Google Scholar 

  11. Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams CD, Manolagas SC (1992) 17β-Estradiol inhibits interleukin-6-production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 89: 883

    Google Scholar 

  12. Grant S, Bhalla K, Arlin Z, Howe CW (1990) The effect of a prolonged in vitro exposure to 1-β-d-arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) myeloid progenitor cells in suspension culture. Exp Hematol 18: 41

    Google Scholar 

  13. Grant S, Pettit GR, McCrady C (1992) Effect of bryostatin 1 on the in vitro radioprotective capacity of recombinant granulocytemacrophage colony-stimulating factor (rGM-CSF) toward committed human myeloid progenitor cells (CFU-GM). Exp Hematol 20: 34

    Google Scholar 

  14. Gulshan S, McCruden AB, Stimson WH (1990) Oestrogen receptors in macrophages. Scand J Immunol 31: 691

    Google Scholar 

  15. Horowitz MC (1993) Cytokines and estrogen in bone: anti-osteoporotic effects. Science 260: 626

    Google Scholar 

  16. Jordan VC (1991) Long-term tamoxifen: balancing benefits and risks. Contemp Oncol 3: 26

    Google Scholar 

  17. Katayama N, Nishikawa M, Minami N, Shirakawa S (1989) Putative involvement of protein kinase C in proliferation of human myeloid progenitor cells. Blood 73: 123

    Google Scholar 

  18. Leonessa F, Jacobson M, Boyle B, Lippman J, Clarke R (1993) The interaction of tamoxifen with the MDR1 P-glycoprotein in multidrug resistant human breast cancer cells. Proc Am Assoc Cancer Res 34: 1933

    Google Scholar 

  19. Leonessa F, Lippman J, Clarke R (1992) Mechanisms of tamoxifen-and ORG2058-induced reversal of the MDR1 phenotype. Proc Am Assoc Cancer Res 33: 485

    Google Scholar 

  20. Marie J-P, Brophy NA, Ehsan MN, Aihara Y, Mohamed NA, Cornbleet J, Chao NJ, Sikic BI (1992) Expression of multidrug resistance genemdr1 mRNA in a subset of normal bone marrow cells. Br J Haematol 81: 145

    Google Scholar 

  21. McCrady CW, Staniswalis J, Pettit GR, Howe C, Grant S (1991) Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte-macrophage progenitors to recombinant GM-CSF. Br J Haematol 77: 1

    Google Scholar 

  22. Michaelevicz R, Lifshitz D, Revel M (1989) Interferon-β2/interleukin-6 and interleukin-3 synergize in stimulating proliferation of early human hematopoietic progenitor cells. Scan Microsc 3: 1143

    Google Scholar 

  23. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB (1985) Inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462

    Google Scholar 

  24. Pastan IP, Gottesman MM (1991) Multidrug resistance. Annu Rev Med 42: 277

    Google Scholar 

  25. Ramu A, Glaubiger D, Fuks Z (1984) Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 44: 4392

    Google Scholar 

  26. Rogan AM, Hamilton TC, Young RC, Klecker RW, Ozols RF (1984) Reversal of Adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994

    Google Scholar 

  27. Rowley SD, Zuehisdorf M, Braine HG, Colvin OM, Davis J, Jones RJ, Saral R, Sensenbrenner LL, Yeager A, Santos GW (1987) CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxy-cyclophosphamide-purged bone marrow. Blood 70: 271

    Google Scholar 

  28. Smith MA, Merry S, Smith JG, Kaye SB (1988) Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to Adriamycin and VP-16. Br J Cancer 57: 576

    Google Scholar 

  29. Speth PAJ, Raijmakers RAP, Boezeman JBM, Linssen PMC, De Witte TJM, Wessels HMC, Haanen C (1988) In vivo cellular Adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells. Eur J Clin Oncol 24: 667

    Google Scholar 

  30. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735

    Google Scholar 

  31. Tormey DC, Falkson G, Crowley J, Falkson HC, Voelkel J, Davis TE (1982) Dibromodulcitol and Adriamycin±tamoxifen in advanced breast cancer. Am J Clin Oncol 5: 33

    Google Scholar 

  32. Trump DT, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL (1992) High dose oral tamoxifen, a potential multidrug-resistance reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 84: 1811

    Google Scholar 

  33. Yalowich JC, Zucali JR, Gross MA, Ross WE (1985) Effects of verapamil on etoposide, vincristine and Adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemic cells in vitro. Cancer Res 45: 4921

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology/Toxicology, Medical College of Virginia, 23298, Richmond, VA, USA

    Karen E. Woods & David A. Gewirtz

  2. Department of Medicine, Medical College of Virginia, 23298, Richmond, VA, USA

    Steven Grant & Saul Yanovich

Authors
  1. Karen E. Woods
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven Grant
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Saul Yanovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David A. Gewirtz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Woods, K.E., Grant, S., Yanovich, S. et al. Variable effects of tamoxifen on human hematopoietic progenitor cell growth and sensitivity to doxorubicin. Cancer Chemother. Pharmacol. 33, 509–514 (1994). https://doi.org/10.1007/BF00686510

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686510

Keywords

Search

Navigation